Karim Zahidul, Sawada Akira, Kawakami Hideaki, Yamamoto Tetsuya, Taniguchi Takazumi
Department of Ophthalmology, Gifu University Graduate School of Medicine, Japan.
Curr Eye Res. 2006 Mar;31(3):273-83. doi: 10.1080/02713680500536647.
We investigated whether lomerizine, a new diphenylmethylpiperazine calcium channel blocker, exerted a neuroprotective effect on axonal or retinal damage induced by optic nerve injury in the rat.
A partial crush lesion was inflicted unilaterally on the optic nerve, 2 mm behind the globe, in adult Wistar albino rats. Animals were treated with the vehicle, 10 or 30 mg/kg lomerizine. Each solution was given orally twice daily for 4 weeks. One week before euthanization, Fluoro-Gold (FG) was injected into both superior colliculi to retrogradely label surviving retinal ganglion cells (RGCs). Approximately 1 month after the optic nerve injury, the retinal damage was assessed morphologically, and the optic nerve axons surrounding the initial lesion were examined histologically.
The mean RGC density in the control group decreased to 65.9 +/- 1.32% of the contralateral eye, whereas the systemic application of 10 or 30 mg/kg of lomerizine significantly enhanced the RGC survival to 88.1 +/- 0.38% and 89.8 +/- 0.28%, respectively. Histological examination of damaged axons revealed no significant enhancement of the density or total number of axons of the retinal ganglion cells in the lomerizine-treated group. The crush force we employed caused no significant morphological differences in the retinal layers between the sham-operated animals and the animals from the experimental groups.
Our findings suggest that lomerizine alleviates secondary degeneration of RGCs induced by an optic nerve crush injury in the rat, presumably by improving the impaired axoplasmic flow.
我们研究了新型二苯甲基哌嗪类钙通道阻滞剂洛美利嗪是否对大鼠视神经损伤所致的轴突或视网膜损伤具有神经保护作用。
在成年Wistar白化大鼠的眼球后2 mm处单侧对视神经造成部分挤压损伤。动物分别接受溶剂、10或30 mg/kg洛美利嗪治疗。每种溶液每天口服两次,持续4周。在安乐死1周前,将荧光金(FG)注入双侧上丘,以逆行标记存活的视网膜神经节细胞(RGCs)。视神经损伤后约1个月,对视网膜损伤进行形态学评估,并对初始损伤周围的视神经轴突进行组织学检查。
对照组的平均RGC密度降至对侧眼的65.9±1.32%,而全身应用10或30 mg/kg洛美利嗪可使RGC存活率分别显著提高至88.1±0.38%和89.8±0.28%。对受损轴突的组织学检查显示,洛美利嗪治疗组视网膜神经节细胞轴突的密度或总数没有显著增加。我们采用的挤压力在假手术动物和实验组动物的视网膜层之间未引起显著的形态学差异。
我们的研究结果表明,洛美利嗪可能通过改善受损的轴浆运输,减轻大鼠视神经挤压伤所致的RGCs继发性变性。